PRME
Prime Medicine·NASDAQ
--
--(--)
--
--(--)
4.85 / 10
Netural
Analyst sentiment is split between Neutral and Strong Buy with equal 50% representation, yielding a historical weighted rating of 1.79—below the consensus threshold for strong conviction. Conversely, fund-flow metrics shine with a 7.9/10 score and consistently positive trends across block, small, medium, and large orders, hinting at underlying institutional accumulation despite lukewarm analyst enthusiasm.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-10
InstitutionChardan Capital
Times predicted5
Historical Win Rate40.0%
What is the analyst consensus for PRME?
- PRME holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.85/10 (Netural).
